Katherine Bishop
Corporate Officer/Principal at ACADIA PHARMACEUTICALS INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Davis | M | 63 | 10 years | |
| Arthur Suckow | M | - |
DTx Pharma, Inc.
 DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | 7 years |
| Joseph Loscalzo | M | 72 | 10 years | |
| Stephen Biggar | M | 53 | 11 years | |
| Julian Baker | M | 57 | 9 years | |
| Bob Mischler | M | - | 9 years | |
| Julie Fisher | F | - | 6 years | |
| Brendan Teehan | M | 56 | 6 years | |
| Elizabeth Garofalo | M | 66 | 4 years | |
| Mark Schneyer | M | 50 | 4 years | |
| John Grundy | M | - |
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | 7 years |
| James Burns | M | - |
Locanabio, Inc.
 Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 5 years |
| Edmund Harrigan | M | 71 | 9 years | |
| Jeffrey Friedman | M | - |
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | 6 years |
| Alan Joelson | M | - |
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | 3 years |
| Albert Kildani | M | - | 1 years | |
| Roderick D. Fraser | M | 83 |
University of Alberta
| 29 years |
| James Daly | M | 62 | 8 years | |
| Don Soland | M | 65 | 9 years | |
| Laura Brege | F | 66 | 16 years | |
| Jennifer J. Rhodes | F | 53 | - | |
| Timothy Scott | M | - |
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | 7 years |
| Kazenelson Deb | F | - | - | |
| Kim Doan | F | - | 9 years | |
| Benir Ruano | M | - | 2 years | |
| Kevin Oliver | M | - | 1 years | |
| Sanjeev Pathak | M | - | 3 years | |
| Holly Valdiviez | F | - | 2 years | |
| Rob Ackles | M | - | 10 years | |
| Adam Fowler | M | - |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 4 years |
| Laine M. Woollard | M | - |
University of Alberta
| 30 years |
| Kimberly Manhard | F | 64 | - | |
| Adora Ndu | M | 43 | 2 years | |
| Matthew Hammond | M | 35 |
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | - |
| Ponni Subbiah | M | - | 5 years | |
| James Kihara | M | - | 4 years | |
| Rick Chalaturnyk | M | - |
University of Alberta
| 27 years |
| Parag V. Meswani | M | - | 2 years | |
| Dan Becker | M | 49 |
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Elena Ridloff | F | 44 | 3 years | |
| D. Walke | M | 58 | 6 years | |
| Eric Loumeau | M | 61 | 3 years | |
| George Morrow | M | 72 | 3 years | |
| Breaux B. Castleman | M | 83 | 8 years | |
| Lorna Harron | F | - |
University of Alberta
| 6 years |
| David Nelles | M | - |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | 4 years |
| John Stavropoulos | M | - |
University of Alberta
| 7 years |
| Georgia Theofan | M | - |
Ceregene, Inc.
 Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | - |
| Austin Kim | M | 60 | 6 years | |
| Kate van Riper | F | - |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | - |
| Kevin R. Mather | M | 51 |
University of Alberta
| 6 years |
| Srdjan Stankovic | M | 67 | 7 years | |
| James Breitmeyer | M | 70 | 5 years | |
| John Reed | M | 65 | 11 years | |
| Huifen Zhang | F | - |
University of Alberta
| 4 years |
| Darren Hribar | M | - |
University of Alberta
| 3 years |
| Wai Yip Leung | M | 47 |
University of Alberta
| 4 years |
| James C. Lee | M | - |
University of Alberta
| 4 years |
| Todd W. Cooper | M | 59 |
University of Alberta
| 4 years |
| Jason Rosychuk | M | 50 |
University of Alberta
| 4 years |
| Berkley Pennock | M | 47 |
University of Alberta
| 4 years |
| Michael Wasylynchuk | M | - |
University of Alberta
| 4 years |
| Colin Ranger | M | - |
University of Alberta
| 4 years |
| Ming Fai Koh | M | 50 |
University of Alberta
| 4 years |
| Amir Arif | M | - |
University of Alberta
| 4 years |
| Michael Sutton | M | - |
University of Alberta
| 5 years |
| Darren Fast | M | - |
University of Alberta
| 3 years |
| Gregory Bennett | M | 51 |
University of Alberta
| 4 years |
| Rajdeep Saran | M | - |
University of Alberta
| 4 years |
| Jeremy Shepherd | M | - |
University of Alberta
| 4 years |
| David Kallay | M | 52 |
University of Alberta
| 4 years |
| Dillon Seo | M | - |
University of Alberta
| 8 years |
| Zeeshan Syed | M | - |
University of Alberta
| 4 years |
| Banerjee Mila | F | - |
University of Alberta
| 4 years |
| Raymond Schwartzenberger | M | - |
University of Alberta
| 4 years |
| Craig Spreadbury | M | - |
University of Alberta
| 4 years |
| Kristopher Zack | M | - |
University of Alberta
| 4 years |
| Kevin C. H. Lo | M | - |
University of Alberta
| 4 years |
| James D. Jacuta | M | - |
University of Alberta
| 12 years |
| Kevin Yakiwchuk | M | - |
University of Alberta
| 1 years |
| Launa J. Aspeslet | M | - |
University of Alberta
| 3 years |
| Chris C. Bolton | M | - |
University of Alberta
| 5 years |
| Marcus W. Archer | M | - |
University of Alberta
| 3 years |
| Kevin Saskiw | M | - |
University of Alberta
| 4 years |
| Kelly D. Sledz | M | - |
University of Alberta
| 4 years |
| Reg Joseph | M | - |
University of Alberta
| - |
| Amit Monga | M | 56 |
University of Alberta
| 4 years |
| Michael Tanton | M | - |
University of Alberta
| 4 years |
| David S. Kelcher | M | - |
University of Alberta
| 4 years |
| Darren Albert Dansereau | M | - |
University of Alberta
| 4 years |
| Michael Allen | M | 49 |
University of Alberta
| 4 years |
| Derrick Freitag | M | - |
University of Alberta
| 3 years |
| David W. Kobylnyk | M | - |
University of Alberta
| 3 years |
| Desmond Balakrishnan | M | 52 |
University of Alberta
| 3 years |
| Howard Dahl | M | 64 |
University of Alberta
| 4 years |
| Beayue C. Louie | F | - |
University of Alberta
| 4 years |
| Mehdi Gasmi | M | 57 |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | 8 years |
| Linnea Marie McKercher | F | - |
University of Alberta
| 2 years |
| Rachel Colabella | F | - |
University of Alberta
| 3 years |
| Dean Mullin | M | - |
University of Alberta
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 51 | 51.00% |
| United States | 49 | 49.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Katherine Bishop
- Personal Network